Singapore markets close in 3 hours

Idorsia Ltd (IDRSF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
22.800.00 (0.00%)
At close: 1:38PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close22.80
Bid0.00 x 0
Ask0.00 x 0
Day's range22.80 - 22.80
52-week range22.68 - 33.25
Avg. volume1,513
Market cap3.814B
Beta (5Y monthly)0.70
PE ratio (TTM)N/A
EPS (TTM)-3.39
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Reuters

    Idorsia insomnia drug starts FDA review as founder Clozel's second act proceeds

    Idorsia's insomnia drug was accepted for review by U.S. regulators, the Swiss drugmaker said on Wednesday, as founder Jean-Paul Clozel edges closer to bringing his new company's first drug to market since selling Actelion for $30 billion. The U.S. Food and Drug Administration agreed to consider the medicine daridorexant for approval, as Idorsia seeks to go up against a similar drug, Merck's Belsomra, which last year racked up $327 million in sales. Clozel, along with his wife, Martine Clozel, Idorsia's chief science officer, founded Actelion two decades ago and turned it into Switzerland's most-successful homegrown biotech startup in recent years before unloading the business to Johnson & Johnson in 2017.

  • Reuters

    Idorsia raises $600 million to support insomnia drug launch

    Swiss drugmaker Idorsia on Wednesday raised 535.5 million Swiss francs ($592.30 million) from a capital increase to help launch and market its experimental insomnia drug, should it win approval from regulators. Idorsia plans to file for approval for daridorexant in the United States later this year and is already building up a sales team, in hopes of getting a swift nod from the U.S. Food and Drug Administration. Company founders Jean-Paul and Martinne Clozel, who have more than 25% of the company's shares, are aiming to duplicate their success with Actelion, where the husband and wife team built one of Switzerland's rare biotech startup success stories before selling to Johnson & Johnson for $30 billion in 2017.